These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33314287)

  • 21. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
    González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
    Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytomegalovirus-associated thrombocytopenia treated with thrombopoietin receptor agonist.
    Simpson JD; Matthews GV; Brighton TA; Joseph JE
    Intern Med J; 2016 Sep; 46(9):1096-9. PubMed ID: 27633469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers.
    Aslanis V; Zhang J; Lomeli B; Grosch K; Ouatas T
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):847-855. PubMed ID: 30171280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia.
    González-López TJ; Sánchez-González B; Pascual C; Arefi M; de Cabo E; Alonso A; Martín-Salces M; Jiménez-Bárcenas R; Calbacho M; Galan P; Barez A; González-Porras JR
    Platelets; 2015; 26(1):83-6. PubMed ID: 24499036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review.
    Wang XL; Li AM
    Blood Coagul Fibrinolysis; 2016 Oct; 27(7):825-827. PubMed ID: 26650460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
    Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
    Kowalczyk M; Rubinstein PG; Aboulafia DM
    J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eltrombopag: a novel oral thrombopoietin receptor agonist.
    Corman SL; Mohammad RA
    Ann Pharmacother; 2010 Jun; 44(6):1072-9. PubMed ID: 20460556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.
    Scaramucci L; Giovannini M; Niscola P; Tendas A; Perrotti A; De Fabritiis P
    Blood Transfus; 2014 Oct; 12(4):605-7. PubMed ID: 25351191
    [No Abstract]   [Full Text] [Related]  

  • 30. Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model.
    Neves DV; Vieira CP; Rocha A; Lanchote VL
    J Pharm Pharm Sci; 2018; 21(1):236-246. PubMed ID: 29949502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eltrombopag--an oral thrombopoietin agonist.
    Sharma V; Randhawa H; Sharma A; Aggarwal S
    Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.
    Gibiansky E; Zhang J; Williams D; Wang Z; Ouellet D
    J Clin Pharmacol; 2011 Jun; 51(6):842-56. PubMed ID: 20663993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR
    Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe immune thrombocytopenia in pregnancy treated with Eltrombopag - A case report.
    Ferreira IJMCF; Sousa F; Vasco EM; Areia ALFA; Moura JPAS; Carda J; Ribeiro L
    J Gynecol Obstet Hum Reprod; 2018 Oct; 47(8):405-408. PubMed ID: 29981476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eltrombopag-Induced Acute Liver Failure in a Pediatric Patient: A Pharmacokinetic and Pharmacogenetic Analysis.
    Marano M; Serafinelli J; Cairoli S; Martinelli D; Pisani M; Palumbo G; Cefalo MG; Cecchetti C; Di Nardo M; Falvella FS; Goffredo BM
    Ther Drug Monit; 2018 Aug; 40(4):386-388. PubMed ID: 29683873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Br J Clin Pharmacol; 2018 Nov; 84(11):2673-2677. PubMed ID: 30032487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TGFβ(1) and sCTLA-4 levels are increased in eltrombopag-exposed patients with ITP.
    Fujita S; Nakanishi T; Yoshimura H; Hotta M; Nakamichi N; Tamaki T; Ishii K; Ito T; Nomura S
    Thromb Res; 2012 Sep; 130(3):415-9. PubMed ID: 22789125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia].
    Horikoshi A; Tsukuda J; Abe R; Fujiwara N; Ito E; Takaku T
    Rinsho Ketsueki; 2016 May; 57(5):638-41. PubMed ID: 27263792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there a role for low-dose eltrombopag as maintenance therapy in the treatment of immune thrombocytopenia?
    Vlachaki E; Sousos N; Perifanis V; Kaiafa G; Onoufriadis I; Hatzitolios A; Boura P
    Acta Haematol; 2015; 133(1):78-82. PubMed ID: 25170628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.